via Johns Hopkins University
Antibody injections are a highly desirable treatment for people with chronic diseases such as cancer, psoriasis, Crohn’s disease and arthritis. And recently, antibodies have been in the news as a promising treatment for severe cases of COVID-19.
But the costly, time-consuming manufacturing process to produce antibodies prevents these treatments from being accessible to most patients.
Andrew Zydney, Bayard D. Kunkle Chair and professor of chemical engineering at Penn State, has identified a new method to manufacture antibodies, which could drive down the production cost. His research results were recently published in Biotechnology Progress.
“If you look at the top 10 best-selling medications, by annual sales, eight are in the category of monoclonal antibodies,” Zydney said. “And every year, individuals and insurance companies spend upwards of $100 billion on antibodies, with costs to treat a single patient often exceeding $50,000. There remains a huge unmet need for these products in treating a growing range of diseases.”
Known as precipitation, Zydney’s new protein purification process involves adding zinc chloride and polyethylene glycol, a water-soluble polymer, to a solution containing the antibody. This causes the antibody to precipitate so that the impurities can be washed away.
Though the precipitation process has been used for 70 years in blood plasma processing, it has never been used for the commercial production of antibodies, according to Zydney.
“To precipitate means ‘to come out’ of a solution in a solid form,” he said. “For example, when you put salt in warm water, it dissolves. But if you put a lot of salt into cold water, some of that salt will remain as solid crystals. In the same way, proteins would normally dissolve in a solution, but you can find certain conditions where they come out as solid.”
Zydney explained that the zinc chloride used in precipitation is a simple salt, making it much cheaper than other purification methods. It also saves time, as it is possible to yield large quantities of proteins in short periods of time.
Currently, antibodies are produced using a process called Protein A affinity chromatography, where the antibody binds to Protein A, which is immobilized in a chromatography column. The impurities can be washed away from the bound antibody, after which the pH level is adjusted to recover the purified antibody product. A single Protein A chromatography column can cost more than $10 million.
“That is just one step in the current manufacturing process, and it is what makes antibody manufacturing so expensive,” Zydney said. “All of the major biotechnology companies are big players in this space.”
The precipitation process eliminates the need for the costly chromatography process, as antibodies are purified directly from the solution by filtration through hollow fiber membranes.
“What we do in our research group is relatively small scale,” He said. “But the precipitation process has the potential to be easily scaled up, potentially enabling biopharmaceutical companies to produce lower-cost antibodies for the patients who need them.”
Todd Przybycien, professor of chemical and biological engineering at Rensselaer Polytechnic Institute, contributed to this research.
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
- Pfizer, Gilead, Roche seen benefitting the most from antibody-drug conjugates
Antibody-drug conjugates, a relatively new class of therapy that is improving cancer treatment, are likely to be a boon for the bottom line of companies marketing and developing them. In 2028, revenue ...
- HKUMed develops groundbreaking monoclonal antibody for treating cerebral ischaemia injury
A research team from the LKS Faculty of Medicine at the University of Hong Kong (HKUMed) has successfully developed a neutralising monoclonal antibody, 6H2, which targets a harmful protein known to ...
- Alternating Arm of Vaccine Shot Increases Antibody Response to COVID-19 Vaccine
injections relative to their initial vaccination. The ipsilateral and contralateral cohorts were made up mostly of women (72% and 75%, respectively) and had a mean age of 44.6 (SD, 12.7) and 44.2 (SD, ...
- New monoclonal antibody for treating cerebral ischemia injury
Through pre-clinical experiments on animals, the team found that the 6H2 antibody effectively attenuates ischemic stroke injury, offering potential for a highly effective pharmacological therapy for ...
- Antibody Therapy Market on Track to Surpass a Staggering US$ 824.0 Billion by 2033
With ongoing research and development efforts, the market for antibody therapy is setting the standard for cutting-edge medical treatments and providing hope for improved patient outcomes for a range ...
Go deeper with Google Headlines on:
[google_news title=”” keyword=”antibody injections” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]
Go deeper with Bing News on:
- U.S. researchers identify new antibodies targeting "dark side" of influenza virus protein
Researchers at the U.S. National Institutes of Health (NIH) have identified antibodies targeting a hard-to-spot region of the influenza virus, the agency said on Friday. The research results, ...
- Bioconjugates Meet and Promise to Exceed Expectations
In bioconjugates, the biologic needn’t be an antibody. It can be a more complex molecule. And the payload needn’t be an anticancer drug. It can be some other kind of drug. The production of ...
- Pfizer fleshes out oncology strategy, targeting 8 blockbuster cancer drugs by 2030
In what CEO Albert Bourla called an update to a top priority at Pfizer, the company on Thursday systemically laid out its new oncology strategy following the $43 billion acquisition of antibody-dru | ...
- The pet drugs vets are now prescribing look a lot more like human medications
New drug treatment options are coming for cats and dogs as the divide between animal and human health is starting to narrow.
- Global Therapeutic Antibody Market Research, 2019-2023 and 2024-2029
Advances in bioprocessing and manufacturing technologies are ongoing. These improvements can lead to increased efficiency, reduced costs, and a more sustainable production of therapeutic antibodies.
Go deeper with Google Headlines on:
[google_news title=”” keyword=”antibody manufacturing” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]